Evaluating body composition's impact on chemotherapy toxicity in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates how fat-free mass and other clinical and biochemical parameters relate to the toxicity experienced by patients undergoing treatment with Carboplatin and Paclitaxel for advanced Non-Small Cell Lung Cancer (NSCLC). It aims to understand the role of body composition in predicting adverse effects of chemotherapy, particularly in a population where malnutrition and sarcopenia are prevalent. By analyzing these associations, the study seeks to improve treatment outcomes and quality of life for patients with advanced lung cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)
* Candidates for treatment with carboplatin plus paclitaxel 1st line
* Performance status (ECOG 0-2)
* Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)
* Normal renal ultrasound prior to initiation of treatment

Exclusion Criteria:

* Patients with renal impairment (KDOQI 3-5)
* Patients who do not have computed tomography study at baseline
* Uncontrolled blood pressure (\> 140 mmHg)
* Uncontrolled diabetes (\> 130 mg / dL)
* Obstruction in kidney (s) or ureter (s)
* Dehydrated patients
* Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.\> 1 month)

Where it's running

• Instituto Nacional de Cancerologia
  Mexico City, Mexico Recruiting

Study contacts

• Principal investigator: Oscar Arrieta, MD, MSc — Instituto Nacional de Cancerologia, Columbia
• Study coordinator: Oscar Arrieta, MD, M Sc
• Email: ogar@unam.mx
• Phone: 015556280400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing muscle loss in lung cancer patients using imaging techniques

  This study is testing a new way to use ultrasound and scans to find muscle loss in lung cancer patients to see if catching it early can help improve their treatment and recovery.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT06327594

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Sarcopenia in Patients After Cardiac Surgery

  This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07908472

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

• Bone marrow mesenchymal stem cell injection for sarcopenia

  This study tests whether CG-BM1, a stem cell injection, can be safely given to adults with sarcopenia to see if it helps improve muscle health.

  Recruiting Phase 1/2 GuangZhou Cellgenes Biotechnology Co., Ltd. · Guangzhou · NCT07865676

• GLP-1 receptor agonist use and muscle health in adults with obesity without diabetes

  This study tests whether GLP-1 receptor agonists affect muscle mass and strength in adults with obesity who don’t have diabetes.

  Recruiting Istanbul Saglik Bilimleri University · Istanbul, Kucukcekmece · NCT07858864

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.